Ku is a heterodimeric protein which is composed of Ku70 and Ku80.DNA dependent protein kinase is composed of Ku and DNA dependent protein kinase catalytic subunit (DNA-PKcs).DNA double strands break is the main method that radiation kill tumor cell,which will restraint DNA repair,and induce cell apoptosis.Ku protein is the key point in the repair of DNA.Blocking Ku protein will increase the radiosensitivity of tumor cell.

Objective To observe the therapeutic effectiveness of valsartan in combination with amlodipine in therapy of essential hypertension and the consequent changes in red cell distribution width (RDW).Methods One hundred and ten patients of hypertension were selected,then randomly divided into treatment group (56 cases) and control group (54 cases).Valsartan and amlodipine were given to the treatment group,while the control group taking amlodipine only.Bp and RBC were carried out before and after treatment.Results Antihypertensive effect of the treatment group were statistically significant compared with the control group (P ＜ 0.05).The consequent RBC,Hct and Hb,RDW level of treatment group decreased dramatically compared with the control group (P ＜ 0.01 or ＜ 0.05).Conclusions Valsartan in combination with amlodipine in ther apy of hypertension is a prospective combination which achieves superior blood pressure control,low level of RDW and blood viscosity,as a result reducing the incidence of cardiovascular events.

Objective:Discuss and analyze the mechanisms of spine fine adjusting through the observation of the therapeutic effect in treating cervical spondylotic radiculopathy(CSR)and the conversion of cervical curvature.Methods: Randomly divide 106 CSR patients into two groups–manipulation therapy group and traction therapy group,53 for each.Judge the therapeutic effect by evaluation scales and measure the cervical curvature on X-ray photographs.Results:The symptoms and physical signs of the patients in both two groups have been improved(P

Objective To evaluate the efficacy and safety of lenalidomide in a real-world clinical practice in Chinese patients with multiple myeloma (MM).Methods It was a prospective,multi-center,observational study.A total of 165 consecutive patients with MM treated with lenalidomide-based regimens were enrolled in 12 hospitals from June 2013 to November 2015.Relevant information was recorded,such as baseline clinical data,cytogenetic abnormalities,treatment regimens,and duration of treatment,safety,and survival.Results (1)There were 126 relapsed and refractory MM (RRMM) patients,25 newly diagnosed patients and 19 maintenance patients.The evaluable RRMM patients accounted for 120 cases,among which 74 cases(61.7％) reached the partial response (PR) or above,and a very good partial response (VGPR) in 16 patients (13.3％),a complete response (CR) in 14 cases (11.7％),a strictly complete response (sCR) in 4 cases (3.3％).Thus,a VGPR or above in 34 patients accounted for 28.3％.(2)The median follow-up was 13 months,the median time to progression 12 months.The median survival after receiving lenalidomide was 19 months,and the median overall survival (OS) was 62 months.(3) The univariate analysis in 120 RRMM patients suggested that prognostic factors for significant improvement in PFS included normal karyotype,international staging system (ISS) Ⅰ-Ⅱ,t(4;14) negative (detected by fluorescence in situ hybridization),non-bortezomib resistance and response to previous regimens.As to OS,nonbortezomib resistance,response to previous regimens and non-primary refractoriness were positive factors.Multivariate analysis showed that the response to previous regimens (PR or better) was an independent good prognostic factor for progress-free survival (PFS),non-bortezomib resistance and non-primary refractoriness for OS.(4) Grade 3 or 4 adverse events that occurred in more than 10％ of all enrolled patients were neutropenia (12.7％),leukocytosis (11.5％) and thrombocytopenia (12.7％).Owing to intolerance of toxic side effects,7 cases withdrew lenalidomide.Conclusions No matter what combination,regimens containing lenalidomide are effective to RRMM patients with overall response rate 61.7％,a time to progression 12 months and an overall survival 62 months.The toxicity is quite tolerable and manageable.In addition,the response to previous treatment (reached PR or above) is the independent good prognostic factor for PFS,non-bortezomib resistance and non-primary refractoriness for OS.Clinical trail registration Clinicaltrials.gov,NCT01947309